Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Waters and Ireland's NIBRT Partner on Training and Research

Published: Thursday, September 27, 2012
Last Updated: Wednesday, September 26, 2012
Bookmark and Share
The partnership will increase large molecule characterization capacity and knowledge, helping to deliver new, more effective therapeutic options.

The Irish National Institute for Bioprocessing Research and Training (NIBRT) and Waters® Corporation have announced that they have formed a multi-level partnership designed to support advanced concepts and deliver the promise of more effective biotherapeutic innovations addressing the world's most challenging diseases through both training and research.

Waters and NIBRT have established the Complete Product and Processing Characterization Facility (CPPCF) for hands-on laboratory based scientific training and retraining of 'fit-for-purpose' biopharmaceutical analysis, including protein and peptide characterization.

The CPPCF's goal is to provide comprehensive training of industry and governmental technicians and scientists to help the burgeoning industry develop advanced biotherapeutic characterization.

The new facility will also educate scientists on existing and upcoming U.S. and European drug regulations.

Furthermore, the partnership establishes NIBRT as a Waters Center of Innovation in the area of glycobiology research.

Prof. Pauline Rudd, NIBRT's principal investigator, and her team will be working with Waters mass spectrometry based systems to take challenging glycan characterization to the next level.

By improving understanding of glycan chemical and molecular structure, scientists can better understand safety and efficacy profiles for a potential molecule, leading directly to novel biotherapeutic options.

Officiating the opening ceremonies for the two new laboratories, Mr. Sean Sherlock TD, Minister for Research and Innovation, Department of Jobs, Enterprise & Innovation commented, "The combination of Pauline Rudd's expertise in glycan analysis and Waters technology for analysis of complex biological samples provides a unique combination of capabilities that can help underpin Ireland's continued reputation as a centre of excellence for the very highest quality standards in biopharmaceutical manufacturing. I'm truly delighted to announce this collaboration as it will surely assist both NIBRT and Waters in further cementing their reputation as providers of choice for the biopharmaceutical industry and Ireland's reputation as a world leading location for biotech manufacturing."

Biopharmaceuticals are increasingly important to patients and drug manufacturers. By 2014, it is expected that 50% of the top 100 prescribed medications will be biopharmaceuticals, including four of the top five selling drugs.

Welcoming this partnership, NIBRT's Interim Director Prof Ian Marison commented, "Ireland is a leading location globally for the development and manufacture of complex biopharmaceutical drugs. This is due in large part to a sustained commitment to quality and compliance with the highest regulatory standards.

"NIBRT was created by the Irish government to underpin the biopharmaceutical industry. One key area that NIBRT will focus on is research into improved product analytics to assist the industry in maintaining exacting quality standards. A second key area is bioanalytical training in the most modern and advanced analytical methods.

"This is being achieved through a major partnership with Waters, who are world leaders in analytical equipment development. This partnership will enable NIBRT, with the help of Waters, to provide advanced solutions for the pharmaceutical industry, including protein characterization, N- and O- glycan analysis."

Waters is the leader in biopharmaceutical analytical technology, which is fundamental to the advancement of biopharmaceuticals.

The company offers a comprehensive technology solution that gives biopharmaceutical manufacturers the analytics they need from discovery to development to commercialization and everything in between.

"Through this lab and other collaborations, Waters will work with industry to improve the development of biopharmaceuticals and inform governments on the types of regulations that should be put in place," said Mike Harrington, Waters Vice President, European Operations.

Industry and government biopharmaceutical leaders in Europe and beyond applauded the Waters-NIBRT partnership.

Waters' effort with NIBRT is the latest demonstration of the company's commitment to creating partnerships that enable it to multiply its impact on critical public health issues, including food safety, safe drugs and clean water.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Waters Selects Prof. Pauline Rudd for Center of Innovation Program Honors
Waters-NIBRT partnership advances biopharmaceutical research, characterization and training.
Friday, April 06, 2012
Waters, Ireland’s NIBRT Partner on Training and Research to Advance Burgeoning Biopharma Industry
Will increase large molecule characterization capacity and knowledge, help deliver new, more effective therapeutic options.
Tuesday, April 03, 2012
Waters and Tecan Sign Agreement for Clinical Assay Platform
The agreement will address the growing need for greater efficiencies and throughput that can be obtained with the automation of routine clinical laboratory assays.
Wednesday, January 18, 2012
Scientific News
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
Crouching Protein, Hidden Enzyme
A new study led by scientists at The Scripps Research Institute (TSRI) and the University of California (UC), Berkeley shows how a crucial molecular enzyme starts in a tucked-in somersault position and flips out when it encounters the right target.
Utilizing Antibodies from Ebola Survivors
A collaborative team from The University of Texas Medical Branch at Galveston, Vanderbilt University, The Scripps Research Institute and Integral Molecular Inc. have learned that antibodies in the blood of people who have survived a strain of the Ebola virus can kill various types of Ebola.
Engineering Foe into Friend
Bose Grant awardee Jacquin Niles aims to repurpose the malaria parasite for drug delivery.
Important Regulator of Immune System Decoded
Plasma cells play a key role in our immune system. Now scientists at the Research Institute of Molecular Pathology (IMP) in Vienna, Austria, and at the Walter and Eliza Hall Institute (WEHI) in Melbourne, Australia, succeeded in characterizing a central regulator of plasma cell function.
Bacterial Superglue for Faster Vaccine Development
An interdisciplinary team of Oxford University researchers has devised a new technique to speed up the development of novel vaccines.
Enumeral, MD Anderson Enter Into Collaboration
Strategic collaboration aims to discover and develop potentially novel antibodies against specified targets for immunotherapy.
Joint venture for GlycoMar Limited and MicroA AS
Scottish biotechnology company GlycoMar and Norwegian technology company MicroA are pleased to announce their joint venture business Prasinotech Ltd. The new company is registered in Scotland.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!